Citius Pharmaceuticals, Inc. (CTXR): Price and Financial Metrics

Citius Pharmaceuticals, Inc. (CTXR): $1.32

0.01 (+0.76%)

POWR Rating

Component Grades













Add CTXR to Watchlist
Sign Up

Industry: Biotech



in industry

CTXR Stock Price Chart Interactive Chart >

Price chart for CTXR

CTXR Price/Volume Stats

Current price $1.32 52-week high $2.01
Prev. close $1.31 52-week low $0.77
Day low $1.27 Volume 770,300
Day high $1.35 Avg. volume 1,286,278
50-day MA $1.09 Dividend yield N/A
200-day MA $1.08 Market Cap 193.00M

Citius Pharmaceuticals, Inc. (CTXR) Company Bio

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

CTXR Latest News Stream

Event/Time News Detail
Loading, please wait...

CTXR Latest Social Stream

Loading social stream, please wait...

View Full CTXR Social Stream

Latest CTXR News From Around the Web

Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity.

Investing in Citius Pharmaceuticals Inc. (CTXR) might be a great opportunity, but the stock is a bit overvalued

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) marked $1.13 per share on Tuesday, up from a previous closing price of $1.12. While Citius Pharmaceuticals Inc. has overperformed by 0.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CTXR fell by -23.65%, with highs and lows ranging from $2.01 to […]

US Post News | January 18, 2023

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Could See Prices Soar In The Coming Months

In today’s recent session, 2.76 million shares of the Citius Pharmaceuticals Inc. (NASDAQ:CTXR) have been traded, and its beta is 1.21. Most recently the company’s share price was $1.20, and it changed around $0.07 or 6.19% from the last close, which brings the market valuation of the company to $149.02M. CTXR at last check was … Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Could See Prices Soar In The Coming Months Read More »

Marketing Sentinel | January 18, 2023

Sidoti's January Micro-Cap Conference

Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.

Yahoo | January 17, 2023

Here's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | January 16, 2023

Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.

Yahoo | January 11, 2023

Read More 'CTXR' Stories Here

CTXR Price Returns

1-mo 54.91%
3-mo 17.86%
6-mo 46.08%
1-year -6.38%
3-year 6.45%
5-year -69.59%
YTD 67.09%
2022 -48.70%
2021 50.98%
2020 0.00%
2019 -1.92%
2018 -72.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.702 seconds.